08:57 AM EST, 12/06/2024 (MT Newswires) -- Verrica Pharmaceuticals ( VRCA ) said Friday its development and commercialization partner Torii Pharmaceutical submitted a new drug application in Japan for TO-208, marketed as Ycanth in the US, to treat molluscum contagiosum skin infection.

The company said a phase 3 study in Japan of TO-208 in patients with molluscum contagiosum met its primary efficacy endpoint and showed that the drug's safety profile is consistent with prior studies in the US.

Verrica said it entered into an exclusive license agreement with Torii in 2021 for the development and commercialization of TO-208 for the treatment of molluscum and common warts in Japan.

Verrica shares were more than 9% higher in recent premarket activity.